Arcutis Biotherapeutics, Inc. (ARQT) has a negative trailing P/E of -192.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 74.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -0.52%, forward earnings yield 1.35%. PEG 1.01.
Criteria proven by this page:
Overall SharesGrow Score: 62/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -4.6 | 0.00 | -4.61 | 0.00 | - |
| 2018 | -41.0 | 0.46 | -32.93 | 0.00 | - |
| 2019 | -19.8 | -0.18 | 8.18 | 0.00 | - |
| 2020 | -7.4 | -0.03 | 3.71 | 0.00 | - |
| 2021 | -5.0 | -0.51 | 3.44 | 0.00 | - |
| 2022 | -2.6 | -0.07 | 3.89 | 220.96 | - |
| 2023 | -0.9 | 0.03 | 2.52 | 3.76 | - |
| 2024 | -12.0 | 0.17 | 10.70 | 8.57 | - |
| 2025 | -228.9 | 2.58 | 19.50 | 9.82 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-0.14 | $0.00 | $-4.98M | - |
| 2018 | $-0.53 | $0.00 | $-19.26M | - |
| 2019 | $-1.10 | $0.00 | $-42M | - |
| 2020 | $-3.80 | $0.00 | $-135.68M | - |
| 2021 | $-4.17 | $0.00 | $-206.36M | - |
| 2022 | $-5.66 | $3.69M | $-311.46M | -8449.8% |
| 2023 | $-3.78 | $59.61M | $-262.14M | -439.8% |
| 2024 | $-1.16 | $196.54M | $-140.04M | -71.3% |
| 2025 | $-0.13 | $376.07M | $-16.14M | -4.3% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.34 | $0.08 – $0.56 | $495.75M | $491M – $500.65M | 5 |
| 2027 | $1.21 | $0.84 – $1.45 | $643.34M | $633.82M – $652.85M | 5 |
| 2028 | $1.99 | $1.44 – $2.79 | $782.88M | $782.88M – $782.88M | 6 |
| 2029 | $2.63 | $2.57 – $2.77 | $920.55M | $903.72M – $957.04M | 4 |
| 2030 | $3.06 | $2.99 – $3.22 | $1.06B | $1.04B – $1.1B | 2 |
